These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3421459)

  • 41. Is your patient susceptible to malignant hyperthermia?
    Dixon BA; O'Donnell JM
    Nursing; 2006 Dec; 36(12 Pt.1):26-7. PubMed ID: 17135899
    [No Abstract]   [Full Text] [Related]  

  • 42. Intravenous dantrolene in a patient with myasthenia gravis.
    Mora CT; Eisenkraft JB; Papatestas AE
    Anesthesiology; 1986 Mar; 64(3):371-3. PubMed ID: 3954134
    [No Abstract]   [Full Text] [Related]  

  • 43. Management of malignant hyperthermia susceptible parturients.
    Pollock NA; Langton EE
    Anaesth Intensive Care; 1997 Aug; 25(4):398-407. PubMed ID: 9288384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A talisman to ward off the bad anaesthetics.
    Mearns CA
    Anaesthesia; 2002 Sep; 57(9):943. PubMed ID: 12240620
    [No Abstract]   [Full Text] [Related]  

  • 45. Muscle biopsy for malignant hyperthermia screening in children.
    Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
    Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Malignant hyperthermia--still a current and dangerous problem].
    Løvstad RZ; Halvorsen P; Steen PA; Lindal S
    Tidsskr Nor Laegeforen; 1995 May; 115(12):1494-8. PubMed ID: 7770853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anaesthetic management of a parturient patient with a malignant hyperthermia partner.
    Dolan R; Corcoran F
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Malignant hyperthermia.
    Sessler DI
    Acta Anaesthesiol Scand Suppl; 1996; 109():25-30. PubMed ID: 8901933
    [No Abstract]   [Full Text] [Related]  

  • 49. Preanesthetic evaluation and management of malignant hyperthermia in the pig experimental model.
    Short CE; Paddleford RR; McGrath CJ; Williams CH
    Anesth Analg; 1976; 55(5):643-53. PubMed ID: 987720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Malignant hyperthermia and day stay surgery.
    Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K
    Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.
    Pollock N; Langtont E; Stowell K; Simpson C; McDonnell N
    Anaesth Intensive Care; 2004 Aug; 32(4):502-9. PubMed ID: 15675210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The anesthetic management of a patient with the malignant hyperthermia trait diagnosed preoperatively].
    Fujiwara K; Takenaka T; Okada S; Nomiyama S; Watanabe S; Tanaka R
    Masui; 1991 Jun; 40(6):978-81. PubMed ID: 1875546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignant hyperthermia.
    Ellis FR; Hassall PJ; Hopkins PM
    Anaesth Intensive Care; 1993 Dec; 21(6):894-5. PubMed ID: 8122763
    [No Abstract]   [Full Text] [Related]  

  • 54. Prediction of malignant hyperthermia susceptibility by clinical signs.
    Larach MG; Rosenberg H; Larach DR; Broennle AM
    Anesthesiology; 1987 Apr; 66(4):547-50. PubMed ID: 3565822
    [No Abstract]   [Full Text] [Related]  

  • 55. Sufentanil-midazolam anesthesia in malignant hyperthermia.
    Tuman KJ; Spiess BD; Wong CA; Ivankovich AD
    Anesth Analg; 1988 Apr; 67(4):405-8. PubMed ID: 2895595
    [No Abstract]   [Full Text] [Related]  

  • 56. Eltanolone (5-beta-pregnanolone) does not trigger, and attenuates halothane triggering of, malignant hyperthermia in malignant hyperthermia susceptible swine.
    Harrison GG; Dyer RA; Llewellyn RL; James MF
    Pharmacol Res; 1999 Feb; 39(2):103-6. PubMed ID: 10072700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An unusual anesthetic course in a patient susceptible to malignant hyperthermia.
    Westlund UJ; Fridrich KL; Warner DS; Sokoll MD
    J Oral Maxillofac Surg; 1989 Aug; 47(8):860-4. PubMed ID: 2664105
    [No Abstract]   [Full Text] [Related]  

  • 58. Manufacturer's response to Bilmen and Gillies' manuscript entitled "clarifying the role of activated charcoal filters in preparing an anaesthetic workstation for malignant hyperthermia-susceptible patients".
    Orr J; Sakata D
    Anaesth Intensive Care; 2014 Nov; 42(6):801-2. PubMed ID: 25342416
    [No Abstract]   [Full Text] [Related]  

  • 59. Malignant hyperthermia.
    Britt BA
    Can Anaesth Soc J; 1985 May; 32(3 Pt 2):S40-1. PubMed ID: 4005693
    [No Abstract]   [Full Text] [Related]  

  • 60. Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update.
    Frei D; Stowell KM; Langton EE; McRedmond L; Pollock NA; Bulger TF
    Anaesth Intensive Care; 2017 Sep; 45(5):611-618. PubMed ID: 28911291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.